Psilocybin is Poorly understood

In October of 2017, Scientific Reports accurately characterized the state of the art for psilocybin technology as “showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood.”

Because of psilocybin’s categorization as a Schedule I Controlled Substance, very little research has been done in this area.  Accordingly, the state of the art for psilocybin products is underdeveloped.

In the 1960s, pure synthetic psilocybin (Indocybin®) was marketed by Sandoz for experimental and psychotherapeutic purposes.

Most users of psilocybin consume it by eating mushrooms.  In some extremely rare cases, psilocybin may be consumed in its purified state.

Eating “magic Mushrooms”

Eating mushrooms is the most popular means for administering psilocybin.  Eating mushrooms is probably not the best way to administer the desired active ingredient.  Although more than 200 species of mushrooms contain psilocybin, these mushrooms are often difficult to identify because they look like many other species.

Psilocybe cyanescens is a species of mushroom known to contain psilocybin and psilocin.

Some of those species are poisonous.  And, even when the desired mushrooms are properly identified, those specimens often vary substantially in the amount of the active ingredients present.

Accordingly, there has been virtually no research and development in the psilocybin space.  The state of the art is stuck in the 1960s: consuming mushrooms in some form.

Recent research has shown that psilocybin provides significant benefits for people suffering from depression.  According to a 2017 study published in Scientific Reports, “Treatment with psilocybin produced rapid and sustain antidepressant effects.”